Intended for abnormal uterine bleeding to manage hormonal levels and support menstrual regulation.
Mechanism of Action
This synthetic progestin transforms a proliferative endometrium into a secretory one. It inhibits the secretion of pituitary gonadotropins, which prevents follicular maturation and suppresses ovulation.
Route of Administration
Oral
Onset Time
1–3 days
Duration
24 hours
Contraindications
Pregnancy, History of thromboembolic disorders, Breast cancer, Liver dysfunction
Severe Adverse Events
Pulmonary embolism, Stroke, Vision loss — requires immediate medical attention
Common Side Effects
Nausea, Headache, Breast tenderness
Uncommon Side Effects
Weight gain, Mood changes, Insomnia
Drug Interactions
Rifampin, St. John's Wort, Alcohol, Phenobarbital, Tobacco
Pregnancy Safety Warnings
FDA Category X: Contraindicated during pregnancy. Breastfeeding: Excreted in milk; monitor infant.
Age Restrictions
Clinically recognized for use in post-menarcheal females.
Information related to Cycrin is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
